Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pulmonary hypertension and cor pulmonale

The pulmonary circulation and right ventricle form a functional system in which the heart's ability to propel blood must remain proportionate to the load imposed by the vessels and lungs. Pulmonary hypertension describes a pathological increase in pressure in the pulmonary circulation, whereas cor pulmonale refers to right ventricular changes caused by respiratory diseases or pulmonary vascular disorders. The two terms therefore describe related but distinct aspects: one concerns hemodynamics, the other the cardiac consequences of specific conditions that increase pulmonary vascular load.

The current hemodynamic definition of pulmonary hypertension requires a mean pulmonary arterial pressure greater than 20 mmHg at rest, measured by right heart catheterization. This threshold does not identify a single disease and is insufficient for choosing treatment. Pressure may increase because of vascular disease, left heart disease, respiratory disorders, pulmonary arterial obstructions or combined mechanisms. The right ventricle's ability to adapt to these conditions largely determines exercise tolerance and clinical risk.

Overall, pulmonary hypertension affects at least 1% of the global population according to available estimates, but this frequency encompasses highly heterogeneous conditions and is not equivalent to the prevalence of the rare arterial form. Left heart disease and lung diseases account for the greatest burden in clinical practice, particularly among older adults; congenital heart diseases, rheumatic valvular disease, infections and parasitic diseases also contribute in different geographic settings. There is no single estimate for cor pulmonale applicable to every population, because definitions, causes and methods of recognition differ. Understanding the relationship between the initial disease, circulatory abnormality and cardiac response is therefore more useful than indiscriminately assigning one percentage to all forms.

Causes and mechanisms: from the pulmonary circulation to the right heart

Under normal conditions, the pulmonary vessels accommodate the entire cardiac output with relatively low load. During exercise, the volume of blood requiring oxygenation increases, but recruitment and distension of the vascular bed limit the resulting rise in pressure. Loss of this vascular reserve may precede severe impairment at rest: patients begin experiencing difficulties with physical activities because the system cannot match blood flow to demand. Increased pressure is therefore the result of a functional and structural abnormality, not necessarily the first event in the disease.

The rare form of pulmonary arterial hypertension is dominated by remodeling of the small arteries. Endothelial abnormalities, vasoconstriction, cellular proliferation and matrix deposition progressively narrow the vessels, increasing resistance. Idiopathic, heritable and systemic disease-associated forms share some biological processes without being identical. Genetic predisposition and environmental factors may interact; an associated condition raises suspicion but does not automatically prove that the predominant mechanism is arterial.

Much more often, pressure rises because of a downstream functional impediment. In pulmonary hypertension due to left heart disease, elevated filling pressures are transmitted backward through the veins and capillaries. Over time, a more complex vascular component may develop. This condition can overload the right ventricle but, in the classical sense, is not termed cor pulmonale because the initial determinant is left heart disease. The terminology preserves a substantial clinical distinction: treatment must first address the responsible cardiac problem.

Respiratory diseases act through a different combination of mechanisms. In pulmonary hypertension due to lung diseases, destruction or distortion of the vascular bed is accompanied by inflammation and remodeling; alveolar hypoxia induces vasoconstriction and, if persistent, contributes to vessel wall changes. Not all hypoxemia, however, results from parenchymal lung disease: hypoventilation and reduced environmental oxygen availability require specific interpretation. The severity of ventilatory limitation and circulatory injury do not always progress in parallel.

Another mechanism is persistent arterial obstruction. In chronic thromboembolic pulmonary hypertension, organized material and small-vessel disease reduce the circulation's capacity to transport blood. The condition may be recognized even without a previous clinically documented embolism. Other conditions grouped among the multifactorial forms combine several pathways of injury. Identifying the mechanism therefore has more than a descriptive purpose: it distinguishes diseases for which profoundly different strategies are available, including procedures that can remove part of the obstruction.

Cardiac adaptation, acute and chronic cor pulmonale

The right ventricle's response depends primarily on the magnitude and speed of development of the overload. When the load increases gradually, the myocardium may strengthen its contraction and thicken, maintaining the required flow for some time. If adaptation is inadequate, the ventricle dilates and becomes less efficient; tricuspid regurgitation and right atrial pressure may increase. Transition to heart failure does not correspond to a universal pressure value because ventricular reserve differs between individuals and etiologies.

Cor pulmonale belongs to this causal relationship between pulmonary respiratory or vascular disease and changes in the right heart chambers. It does not require every sign of peripheral congestion to have already appeared: remodeling may precede overt heart failure. Similarly, ankle edema alone does not prove cor pulmonale, as it may be due to venous insufficiency, medications, renal or hepatic disease, or other heart diseases. Diagnosis must document the pathophysiologic connection, rather than simply the coexistence of lung disease and a nonspecific symptom.

In acute cor pulmonale, a rapid rise in afterload confronts a ventricle that has not had time to adapt. A major pulmonary embolism is a typical example; severe respiratory injury may also impose sudden overload. Right ventricular dilatation and interference with left ventricular filling can rapidly reduce systemic output. As a result, pulmonary pressure that is not exceptionally high may accompany shock: the absolute value must be interpreted together with the onset time and cardiac function.

In chronic cor pulmonale, the process develops in the setting of persistent disease. Hypertrophy and remodeling may initially maintain cardiac output but increase myocardial energy requirements and alter its geometry. When fibrosis, perfusion abnormalities and loss of contractile efficiency develop, the system becomes more vulnerable. An infection, arrhythmia or deterioration in gas exchange may precipitate acute decompensation in a previously relatively compensated chronic condition.

The consequences affect both sides of the circulation. Reduced blood ejection toward the lungs limits return to the left heart and can cause low cardiac output; increased right-sided pressures cause venous congestion. The kidneys, liver and gastrointestinal tract are affected by this combination. Patients may thus develop fatigability, salt and water retention, and abdominal symptoms through related mechanisms. Assessing only the lungs or only the echocardiogram is insufficient: severity emerges from the integration of respiratory gas exchange, right ventricular function, systemic perfusion and organ injury.

Clinical manifestations and recognition of suspected disease

The first reported change is often progressive difficulty with usual activities. Exertional dyspnea and fatigue do not specifically indicate pulmonary vascular disease, but become important when they lack an adequate explanation or seem disproportionate to the known disease. It is necessary to establish what the patient could do before and what they can do now, distinguishing a slow reduction in capacity from rapid deterioration. The presence of several diseases makes this assessment more difficult but no less useful.

The onset of dizziness, syncope, chest pain or palpitations suggests that the circulatory response to exertion may be impaired. Exertional syncope, especially if recurrent or associated with worsening, is a warning sign requiring prompt assessment. Sudden chest pain and dyspnea should not automatically be attributed to a chronic condition: they may represent acute events requiring an urgent diagnostic pathway. Hemoptysis, especially when substantial, requires prompt clarification of the source and severity of bleeding.

In advanced stages, lower limb swelling, weight gain due to fluid retention, abdominal distension and early satiety may indicate right-sided congestion. In other patients, hypoxemia and respiratory symptoms predominate. Orthopnea and episodes of nocturnal dyspnea point more toward a left-sided cardiac component, whereas chronic cough and ventilatory limitation suggest lung disease; none of these features excludes the coexistence of other mechanisms. The medical history should therefore avoid premature single-cause explanations, particularly when the course differs from what is expected.

Investigation of causes includes previous emboli, left heart disease, congenital heart diseases, respiratory disorders, medications, substances and family history. Signs of connective tissue disease or liver disease may change the diagnostic direction but do not replace investigations. For example, in systemic sclerosis, dyspnea and reduced diffusing capacity may result from fibrosis, vascular disease or both; the distinction is necessary to avoid choosing treatment based solely on the name of the systemic disease. The absence of a known predisposing factor also does not exclude suspicion when symptoms remain unexplained.

During physical examination, vital signs, oxygenation and perfusion are assessed, followed by cardiac, pulmonary and systemic findings. An accentuated pulmonary component of the second heart sound, a parasternal heave, signs of tricuspid regurgitation, jugular venous distension, hepatomegaly and edema may support suspected right ventricular overload. The examination may nevertheless reveal little in early stages. Clinical discordance is often informative: substantial symptoms with few ventilatory findings, or deterioration unexplained by routine checks, calls for broader investigation. Assessment should follow a reasoned sequence without waiting for every classic sign of heart failure to appear.

Investigations, diagnosis and disease classification

Diagnosis requires distinguishing probability, confirmation and etiology. Echocardiography may indicate that pulmonary vascular overload is probable and demonstrate the heart's response; catheterization directly measures the parameters needed for hemodynamic classification; other investigations identify the causative disease. These roles are not interchangeable. An elevated estimated systolic pressure is insufficient to diagnose the arterial form, while invasive data not interpreted in clinical context may be incorrectly classified.

Initial assessment combines medical history, physical examination, ECG, biomarkers and imaging. Echocardiography considers tricuspid regurgitation velocity alongside right chamber dimensions, function and geometry and left heart findings. Failure to measure the regurgitant jet does not demonstrate normal pressure. Ventricular function must be described with multiple parameters because an individual index may be affected by loading conditions, image quality and geometry. Assessment of valves and left-sided filling pressures is essential to distinguish suspected pulmonary vascular disease from a more common cardiac cause.

Respiratory assessment combines pulmonary function, diffusing capacity, oxygenation and CT when indicated. Investigation of the thromboembolic component requires a specific pathway: ventilation/perfusion scintigraphy retains an important role, and a normal CT pulmonary angiogram obtained to address a different clinical question does not automatically resolve the issue. If compatible defects are found, dedicated imaging defines the lesions and informs subsequent multidisciplinary assessment. Cardiac magnetic resonance imaging can provide accurate quantification of right ventricular function and clarify complex anatomy or shunts.

During right heart catheterization, pulmonary pressure, wedge pressure and cardiac output are measured and vascular resistance is calculated from them. In general terms, the precapillary profile combines elevated mean pressure, non-elevated wedge pressure and increased resistance; the postcapillary profile has elevated wedge pressure and may or may not include an additional resistive component. Measurement quality is essential, especially near diagnostic thresholds. Provocative investigations and vasoreactivity testing are reserved for specific clinical questions and are not interchangeable versions of the same diagnostic procedure.

After confirmation, the diagnostic pathway continues with phenotyping: systemic associations, genetics when indicated, vascular anatomy, right ventricular function and organ impairment define the condition. Risk is not synonymous with pressure and must be reassessed over time through symptoms, exercise capacity, biomarkers and imaging. Prognostic models developed for pulmonary arterial hypertension are not universal tools for every cause. In cor pulmonale, it is also necessary to demonstrate that the right heart abnormality arises from the pulmonary system and to distinguish acute from chronic forms. The useful result is therefore not merely a label, but a description that supports treatment choice and measurement of its effects.

Treatment, prognosis and complications

Treatment follows the underlying cause and cardiopulmonary reserve. In pulmonary hypertension due to left heart disease, cardiac disease and congestion are addressed; in respiratory forms, lung disease, oxygenation and ventilation are optimized; in pulmonary arterial vascular disease, risk-based specific strategies are used; in chronic thromboembolic disease, the possibility of treating the obstruction is assessed. The common aim is to preserve or restore effective circulation, but the means differ. There is no universal vasodilator for all elevated pulmonary pressures.

Treatment of the arterial form includes medications targeting the endothelin, nitric oxide and prostacyclin pathways, often in combination, with additional treatments targeting growth signaling in suitable patients. Disease severity may require continuous infusions and transplantation assessment. These options must not automatically be extended to groups with left heart or respiratory disease: the balance between benefit, congestion and gas exchange changes with the underlying mechanism. Even vasoreactivity identifies only a specific subgroup and does not justify widespread use of calcium channel blockers.

In CTEPH, endarterectomy, angioplasty and medical therapy may address different components of the disease. Decisions require an expert center because lesion distribution, small-vessel disease, comorbidities and procedural expertise influence the options. In acute cor pulmonale, the priority is to remove or promptly treat the precipitating factor and support perfusion; in chronic cor pulmonale, continuity of causal treatment and prevention of deterioration carry greater weight. In both, fluid administration must be guided by hemodynamics rather than the presence of low arterial pressure alone.

Supportive measures include treatment of congestion, oxygen when indicated, supervised rehabilitation for stable patients, prevention of infections and management of comorbidities. Anticoagulation, medications for rhythm control and other treatments require specific indications. Pregnancy, surgery and anesthesia may challenge limited right ventricular reserve and should be planned with specialist input. Prognosis depends on the interaction between the cause, ventricular function, organ injury and response to treatment; percentages derived from a single patient population do not describe the entire spectrum of conditions.

The main complications include right heart failure, arrhythmias, hepatic and renal congestion, hypoxemia and reduced cardiac output. Cardiac dilatation and increased venous pressure promote a vicious cycle in which fluid retention and organ injury further diminish reserve. Hemoptysis, compressive complications of dilated arteries and hemodynamic collapse are less common events or features of advanced phenotypes. Longitudinal monitoring must detect both progression and adverse treatment effects, integrating quality of life, functional capacity and objective findings. Symptom relief is an important outcome, but it takes on fuller meaning when it corresponds to improved balance of the entire cardiopulmonary system.

References
  1. Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618–3731.
  2. Kovacs G et al. Definition, classification and diagnosis of pulmonary hypertension. European Respiratory Journal. 2024;64(4):2401324.
  3. Mocumbi A et al. Pulmonary hypertension. Nature Reviews Disease Primers. 2024;10(1):1.
  4. Hoeper MM et al. A global view of pulmonary hypertension. The Lancet Respiratory Medicine. 2016;4(4):306–322.
  5. Guignabert C et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. European Respiratory Journal. 2024;64(4):2401095.
  6. Hemnes AR et al. Pathophysiology of the right ventricle and its pulmonary vascular interaction. European Respiratory Journal. 2024;64(4):2401321.
  7. Maron BA et al. Pulmonary hypertension associated with left heart disease. European Respiratory Journal. 2024;64(4):2401344.
  8. Shlobin OA et al. Pulmonary hypertension associated with lung diseases. European Respiratory Journal. 2024;64(4):2401200.
  9. Kim NH et al. Chronic thromboembolic pulmonary disease. European Respiratory Journal. 2024;64(4):2401294.
  10. Chin KM et al. Treatment algorithm for pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401325.
  11. Anand S et al. Diagnostic Evaluation of Pulmonary Hypertension: A Comprehensive Approach for Primary Care Physicians. Journal of Clinical Medicine. 2023;12(23):7309.
  12. Hoeper MM et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal. 2022;60(1):2102311.
  13. Hoeper MM et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801906.
  14. Fisher MR et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. 2009;179(7):615–621.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.